Ibalizumab Overview

Introduction of Ibalizumab

Ibalizumab is a non-immunosuppressive humanized monoclonal antibody (IgG4κ type) developed by TaiMed Biologics but was first developed by Tanox, now part of Genentech. It was designed to target CD4, the primary receptor for human immunodeficiency virus (HIV). On March 6, 2018, Food and Drug Administration (FDA) approved ibalizumab for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen, with the trade name Trogarzo. It's administered intravenously every 14 days by a trained medical professional. And it is used in combination with other antiretroviral drugs.

Mechanism of Action of Ibalizumab

The process of HIV-1 entry into target cells is initiated when the surface subunit of the HIV-1 envelope glycoprotein (gp120) binds to a cellular CD4 receptor. The resulting conformational changes to the CD4/gp120 complex allow gp120 to bind to a second cellular receptor, chemokine receptor-5(CCR5) or CX chemokine receptor-4 (CXCR4). This co-receptor binding allows the gp41 molecule of the viral envelope to insert into the target cell membrane, ultimately leading to fusion of the viral envelope and cellular membrane. Ibalizumab is a humanized monoclonal antibody of murine origin. Initially reported to bind to an epitope on domain 2 of the extracellular region of CD4, more recent work suggests binding to the interface between domain 1 and domain 2 of CD4, away from the binding site for major histocompatibility complex (MHC) class II molecules. It does not inhibit gp120 binding to CD4, which occurs in the domain 1 region. Instead, ibalizumab appears to exert its antiviral effect by post-binding conformational effects that prevent CD4-bound gp120 from interacting with CCR5 or CXCR4. Other monoclonal antibodies that target domain 1 of CD4 and competitively inhibit gp120 binding have been found to be immunosuppressive due to their interference with MHC class II immune function.

Fig.1 Mechanism of action of ibalizumab

Clinical Projects of Ibalizumab*

Approved Drugs of Ibalizumab**

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Trogarzo	Human immunodeficiency virus type 1 (HIV-1) infection	Injection, Solution	150 mg/mL	Intravenous	TaiMed Biologics USA	March 6, 2018

What We Provide

Therapeutic Antibody

Ibalizumab

We provide high-quality Ibalizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Ibalizumab

** Information presented in the table was collected from the following website:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761065

For research use only. Not intended for any clinical use.